Mr. Etienne Grima reports

CARDIOCOMM SOLUTIONS CLOSES SHARES FOR DEBT TRANSACTIONS

Cardiocomm Solutions Inc. has closed its previously announced shares-for-debt transactions with each of the four directors of the company (see the company's news release dated July 25, 2025). Pursuant to debt settlement agreements dated as of July 24, 2025, between the company and each director, the company has issued an aggregate of 4,162,500 common shares of the company at a deemed price of one cent per share to settle an aggregate of $41,625 in outstanding debt owed by the company to the directors, as follows: Etienne Grima received 1,192,500 shares in settlement of $11,925 of debt; Robert Caines received 1.23 million shares in settlement of $12,300 of debt; Daniel Grima received 1.08 million shares in settlement of $10,800 of debt; and Robin Black received 660,000 shares in settlement of $6,600 of debt. The debt was incurred by the directors for services provided in 2024 and in the first six months of 2025.

The shares will be subject to a four-month hold period expiring Dec. 1, 2025, in accordance with applicable securities laws and the policies of the TSX Venture Exchange.

Each debt settlement transaction with a director is considered to be a related-party transaction as defined under Multilateral Instrument 61-101. Each transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as the fair market value of each transaction does not exceed 25 per cent of the market capitalization of the company as determined in accordance with MI 61-101.

About Cardiocomm Solutions Inc.

Cardiocomm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. Cardiocomm Solutions has earned the ISO 13485 and ISO 27001 certifications, is HIPAA compliant, and holds medical device clearances and sales licences from the United States (Food and Drug Administration) and Canada (Health Canada).

We seek Safe Harbor.